Atacand (candesartan) Real Life Study - Real Life
Study identifier:NIS-CSE-ATA-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A REtrospective study on the effects of cAndesartan vs. Losartan on blood pressure, health care consumption and cardiovascuLar events In a "real-liFe" GP sEtting in Sweden
Medical condition
hypertension
Phase
-
Healthy volunteers
No
Study drug
Candesartan Cilexetil, Losartan
Sex
All
Actual Enrollment
14000
Study type
Observational
Age
17 Years +
Date
Study Start Date: 01 Mar 2008
Primary Completion Date: 01 Feb 2009
Study Completion Date: 01 Feb 2009
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 Candesartan | Drug: Candesartan Cilexetil oral once daily dose Other Name: ATACAND |
| 2 Losartan | Drug: Losartan once daily oral dose Other Name: COZAAR |
Contacts
Investigators
Principal Investigator
Jan Stålhammar
Eriksbergs vårdcentral
